Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

SOHO 2022 | Promising cellular therapies emerging in multiple myeloma

Peter Voorhees • 30 Sep 2022
SOHO 2022
Multiple Myeloma CAR-T NK-Cell Therapy

Peter Voorhees, MD, Levine Cancer Institute, Charlotte, NC, shares some insights into promising cellular therapies emerging in multiple myeloma, including allogeneic CAR-T cells, natural killer (NK) cell therapies, and dual-targeting CAR-T cell products. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Peter Voorhees

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting 11:32
Mechanisms of resistance to immunotherapy in HRMM and overcoming it with multiple antigen targeting
Holly Lee et al. • 24 Oct 2025
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab 4:15
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Peter Voorhees • 30 Sep 2022
The role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents 2:39
The role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents
Peter Voorhees • 30 Sep 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals